Cardiac effects of ebastine and other antihistamines in humans

Drug Safety

Volumn 21, Issue SUPPL. 1, 1999, Pages 69-80

  Moss, Arthur J ^a,c   Morganroth, Joel ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Premier Research   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CAREBASTINE; EBASTINE; ERYTHROMYCIN; KETOCONAZOLE; MACROLIDE; PYRROLE DERIVATIVE; THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FOOD; GERIATRICS; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; LIVER FAILURE; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PEDIATRICS; PRIORITY JOURNAL; QT INTERVAL; SCHOOL CHILD;

EID: 0033428470     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921001-00009     Document Type: Conference Paper

References (43)

1. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36: 233-52
2. 1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. Arch Int Pharmacodyn Ther 1996; 331: 59-73
3. 1 receptor antagonists, ebastine and terfenadine, on human Kv 1.5 channels. Eur J Pharmacol 1997; 326: 257-63
4. Dupuis B, Libersa C, Caron J, et al. Electrophysiological effects of ebastine and carebastine on rabbit Purkinje fibres. US: Rhône-Poulenc Rorer, 1995. (Data on file)
5. Cavero I, Mestre M, Guillon J-M, et al. Preclinical in vitro electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf 1999; 20 Suppl. 1: 19-31
6. Roy M-L, Brown AM. Summary of the effects of ebastine and carebastine on HERG currents expressed in xenopus oocytes [Personal communication]. US: Rhône-Poulenc Rorer, 1996. (Data on file)
7. Llenas J, Bou J, Massingham R. Preclinical safety studies with ehastine. II. Pharmacological effects on the cardiovascular system. Drugs Today 1992; 28 Suppl. B: 29-34
8. 1 antihistamines on animal models of QTc prolongation. Drug Saf 1999; 20 Suppl. 1: 39-44
9. Hey JA, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittel Forschung 1996; 46: 153-8
10. Connell L, Alderfer V, Garcia J. Electrocardiographic evaluation of ebastine in double-blind allergic rhinitis clinical trials. Allergy 1995; 50: 105
11. Morganroth J, Brozovich FV, McDonald JT, et al. Variability of the QT measurement in healthy man, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67: 774-6
12. c interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996; 27: 76-83
13. Moss AJ, Chaikin P, Garcia JD, et al. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exper Allergy 1999; 29 Suppl. 3: 200-5
14. Suplick B, Huang M-Y, Wilson J, et al. A placebo-controlled, double-blind, parallel group cardiac safety and pharmacokinetic study of multiple doses of ebastine in healthy male volunteers. US: Rhône-Poulenc Rorer, 1995: Study 26. (Data on file)
15. Kulp J, Gillen M, Pentikis H, et al. A randomized, blinded, four-way crossover, electrocardiographic study of ebastine 60 mg/day and ebastine 100 mg/day compared to tertenadine 360 mg/day, and ebastine placebo in healthy adult male volunteers. US: Rhône-Poulenc Rorer, 1996: Study 136. (Data on file)
16. Wilson J, Huan M-Y, Garcia J, et al. An open-label interaction study between a single dose of ebastine and multiple doses of ketoconazole on the cardiac functiun and pharmacokinetic profile in healthy adult male volunteers, US: Rhône-Poulenc Rorer, 1994: Study 127. (Data on file)
17. Gillen M, Pentikis H, Rhodes G, et al. Pharmacokinetic and cardiac safety studies of ebastine and loratadine administered with ketoconazole. J Clin Pharmacol 1998; 38: 867
18. Kulp J, Gillen M, Pentikis H, et al. A pharmacokinetic and electrocardiographic evaluation of the interaction between multiple doses of ebastine and erythromycin in healthy adult male volunteers, US: Rhône-Poulenc Rorer, 1996: Study 138. (Data on file)
19. Gillen M, Pentikis H, Rhodes G, et al. Pharmacokinetic and pharmacodynamic interaction of ebastine and crythromycin. J Clin Pharmacol 1998; 38: 878
20. Huang M-Y, Argenti D, Wilson J, et al. Pharmacokinetics and electrocardiographic effect of ebastine in young versus healthy elderly subjects. Am J Ther 1998; 5: 153-8
21. Wilson J, Argenti D, Huang M-Y, et al. An open label, single-dose, pharmacokinetic study of 10 mg of ebastine in volunteers with various degrees of renal insufficiency, US: Rhōnc-Poulenc Rorer, 1993: Study 113. (Data on file)
22. Wilson J, Argenti D, Huang M-Y, et al. An open-label, single-dose, pharmacokinetic study of ebastine 20 mg in volunteers with severe renal insufficiency. US: Rhône-Poulenc Rorer, 1993: Study 128, (Data on file)
23. Huang M-Y, Wilson J, Argenti D, et al. An open-label, single-dose, pharmacokinetic study of 10 mg of ebastine in volunteers wilh cirrhosis of the liver, US: Rhône-Poulenc Rorer, 1993: Study 118. (Data on file)
24. Geary WJ, Huang M-Y. A randomized, placebo-controlled, double-blind, parallel group cardiac safety study of ebastine 15 mg in children. US: Rhône-Poulenc Rorer, 1994: Study 125. (Data on file)
25. Wilson J, Huang M Y, Argenti D, et al. Comparative pharmacokinetics of carebastine/ebastine in moderately renally impaired and healthy volunteers following a single 10 mg dose of ebastine. Pharm Res 1993; 10: S391
26. Huang M-Y, Wilson J, Argenti D, et al. Comparative pharmacokinetics of ebastine/carebastine in liver cirrhosis and healthy volunteers following administration of 10 mg ebastine tablet. Pharm Res 1993; 10: S390
27. Jonkman J, Montay G. A double-blind, placebo-controlled crossover pharmacokinetic interaction study of ebastine 20 mg o.d. (taken on days 1-10) and theophylline 400 mg b.i.d, (taken on days 6-10) in twelve healthy male volunteers. The Netherlands: Rhône-Poulenc Rorer, 1993: Study 008. (Data on file)
28. Dorr MB, Huang M-Y, Garcia J. Single-dose study of the effect of food on the bioavailability of ebastine 10 mg tablets in healthy male volunteers. US: Rhône-Poulenc Rorer, 1994: Study 121. (Data on file)
29. Dorr MB, Huang M-Y, Pandit B, et al. An open-label, two-way crossover, single-dose study of the effects of food on the bioavailability of ebastine 20 mg in healthy male volunteers. US: Rhône Poulenc Rorer, 1993: Study 129. (Data on file)
30. Nelson HS, Bucher B, Buchmeier A, et al. Suppression of the skin reaction to histamine by ebastine. Ann Allergy Asthma Immunol 1995; 74: 442-7
31. Brion N, Pletan Y. Double-blind crossover latin square phase one study of the cardiovascular and antimuscarinic activity of ebastine 10, 20, 30 mg, atropine I mg and placebo after single administration in 10 healthy volunteers. France: Rhône-Poulenc Rorer, 1993: Study 005. (Data on file)
32. Pentikis HS, Huang M-Y, DOIT MB, et al. The effect of food on the bioavailability of ebastine. Am J Ther 1497; 4: 80-4
33. Safety of terfenadine and astemizole. Med Lett Drugs Ther 1992; 34: 9-10
34. 1-receptor antagonists, an EAACI position paper. Allergy 1996; 51: 666-75
35. Nightingale SI. Warning issued on non-sedating antihistamines terfenadine and astemizole. JAMA 1992; 268: 6
36. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8
37. Package insert, Zyrtec, PDR 1997
38. Bruno R, Baille P, Rhodes G, et al. An evaluation of the pharmacokinetic/pharmacodynamic (PK/PD) relationships with ebastine at high exposures. J Clin Pharmacol 1998; 38: 874
39. Morganroth J, Brown AM, Critz, S, et al. Variability of the QTc interval: impact on defining drug effect and low frequency cardiac event. Am J Cardiol 1943; 72: 26B-31
40. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet 1997; 349: 1322
41. Expert Report. Ebastine's effect on cardiac safety. US: Rhône Poulenc Rorer, 1996. (Data on file)
42. 1-antagonists ebastine and loratadine; pharmacokinetic and pharmacodynamic effects. US; Rhône-Poulene Rorer, 1998: Studies 137 and 145. (Data on file)
43. Funck-Bretano C, Jaillon P. Rate-corrected QT interval; techniques and limitations. Am J Cardiol 1993; 72: 17B-22